HWHG (600079)
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufenta...
- Open
- 18.10
- High
- 18.18
- Low
- 18.01
- Prev. Close
- 18.06
- Volume
- 49.83K
- Turnover
- 90.17M
- Avg Price
- 18.10
- Bid/Ask Ratio
- --
- Amplitude
- 0.94%
- 52wk High
- 23.18
- Volume Ratio
- 0.47
- Turnover Ratio
- 0.32%
HWHG Analyst Rating
View moreForecast & Rating
Jul 10, 2026Price forecast
¥22.2122.84%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 21 hours ago
Humanwell unit Yichang Renfu wins China nod for labor pain trial of sufentanil injection
- PUBT · Jun 29 at 08:42 AM
Humanwell unit Hubei Bio-Pharma Industry Tech Institute wins China approval to start trials of HWS113 injection for chronic pruritus
- Zhitong · Nov 3, 2025 at 01:45 AM
HWHG: Pregabalin sustained-release tablets have received the drug clinical trial approval notice
- Zhitong · Oct 30, 2025 at 02:47 AM
HWHG: Shareholders holding more than 5% of shares have completed the commitment to acquire Wuhu Xinfeng's stake
- Zhitong · Oct 13, 2025 at 04:47 AM
HWHG: Dapoxetine Hydrochloride Tablets have obtained the drug registration certificate
- Zhitong · Sep 19, 2025 at 02:38 AM
HWHG: Oxcarbazepine extended-release tablets received a tentative approval number from the U.S. FDA
